|
Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or professional assistance by using a genuine doctor. We aren't mDs. Always consult your physician about Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia Clinical research trials and Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia health trials occur in a lot of of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the potency of new does drugs. The role of the studies / undertakings is to figure out specific human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia. Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia Clinical Trials and other clinical trials permit volunteers to get medical treatment choices before they are available to the general public. Many times the test subjects get professional assistance for free of charge, and occasionally they are compensated for their time. Sometimes there is a cost for a Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia clinical trial. Human subjects often get the best healthcare possible for their Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, medical hazards (perhaps life-threatening), and/or the treatment being ineffectual. Trials are federally governed with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia  Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia
Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia
For Condition: Pneumonia
Status: Recruiting
Sponsor(s): Wyeth-Ayerst Research ,
Synopsis: In this study, we will be assessing the efficacy and safety of tigecycline compared with imipenem/cilastatin in subjects hospitalized with nosocomial pneumonia. Imipenem/cilastatin is a potent broad-spectrum intravenous (IV) antibacterial agent approved for the treatment of serious or severe infections, including lower respiratory tract infections. The study population will consist of subjects with nosocomial pneumonia known or suspected to be caused by gram-positive and/or gram-negative bacteria.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Male or female subjects 18 years of age. BULGARIA Only: Male or female subjects 18 years of age and 70 years of age. - Subjects known or suspected to have acute hospital-acquired pneumonia. Acute hospital-acquired pneumonia is defined as pneumonia with onset of symptoms: a. 48 hours AFTER admission to an acute care hospital or chronic care facility such as a skilled nursing home facility or rehabilitation unit. b. 7 days after a subject is discharged from the hospital. The subject’s initial hospitalization must have been 3 days duration. - Presence of a new or evolving infiltrate on a chest x-ray film. The chest xray must be obtained 48 hours after the subject was admitted to the hospital or chronic care facility. The infiltrate must not be related to another disease process or condition (for example, congestive heart failure or acute respiratory distress syndrome). If a CT scan was used to determine the presence of a new or evolving infiltrate in the lungs and a chest x-ray had not been obtained, a chest x-ray showing an infiltrate must be obtained prior to study entry. - The presence of: a. Fever (within 24 hours prior to randomization) defined as an oral temperature > 38°C/100.4°F, tympanic temperature > 38.5°C/101.2°F, axillary temperature 38.1°C/100.6°F, or a rectal/core temperature > 39°C/102.2°F) or hypothermia defined as rectal/core body temperature < 35°C/95.2°F OR b. Leukocytosis [white blood cell count (WBC) > 10 x 109/L (> 10,000/mm3)]; or > 15% immature neutrophils [bands]; or leukopenia with total WBC < 4.5 x 109/L (< 4,500/mm3). - Presence of at least 2 of the following: a. Cough; b. Dyspnea, tachypnea (respiratory rate 30 per minute), particularly if any or all of these are progressive; c. Pleuritic or inspiratory chest pain; d. Auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony); e. Hypoxemia with a PO2 < 60 mmHg or oxygen saturation < 90% while the subject is breathing room air, as determined by pulse oximetry or arterial blood gas; f. Purulent sputum production or respiratory secretion or a change in sputum character occurring 48 hours after hospitalization; OR g. Respiratory failure requiring mechanical ventilation, in lieu of having 2 of the clinical signs and symptoms listed for criterion # 5. - At time of randomization, all subjects should have a respiratory tract specimen obtained for Gram stain and culture. The respiratory tract specimen may be obtained by the following means listed below: a. Deep expectoration; b. Nasotracheal aspiration; c. Endotracheal aspirated/suctioned specimen; d. Bronchoscopy with bronchoalveolar lavage; e. Bronchoscopy with protected-brush sampling; f. Bronchoscopy with distal protected specimen; g. Pleurocentesis with pleural fluid specimen; h. Transtracheal aspiration; If pleural fluid is obtained, another respiratory tract specimen should also be obtained, if possible. Microscopic examination of the Gram-stained respiratory secretions obtained by deep expectoration or nasotracheal aspiration should show < 10 squamous epithelial cells and > 25 polymorphonuclear cells per field at 100X magnification (low-power, 10X objective) for suitability for culture. All specimens obtained by invasive methods should be cultured. Whenever possible, quantitative culture results (cfu/mL) should be reported for respiratory tract specimens (except for pleural fluid). If quantitative culture results are not available, semi-quantitative results will be accepted. - Institutional Review Board or Independent Ethics Committee approved, signed and dated informed consent form. Informed consent form (ICF) will be obtained from each subject prior to participation in this research study. If any subject is unable to give consent, it may be obtained from the subject’s next of kin or legal representative in accordance with local laws and regulations. Exclusion Criteria: - Presence of any of the following pulmonary conditions: cystic fibrosis; pulmonary malignancy (either primary or metastatic); known bronchial-obstructive or post-obstructive pneumonia; pulmonary abscess; empyema; known or suspected active tuberculosis; bronchiectasis; sarcoidosis; known or suspected pulmonary infection caused by Pneumocystis carinii, mycobacteria, fungi, parasites, or viruses. (Subjects with COPD are not excluded). - Suspected or known Legionella infection. - Concurrent hemodialysis, hemofiltration, peritoneal dialysis, or plasmapheresis. - At time of randomization, presence of sustained shock, defined as: a. systolic blood pressure < 90 mm Hg for > 2 hours despite adequate fluid replacement, with evidence of hypoperfusion or b. need for sympathomimetic agents to maintain blood pressure. Note: The use of sympathomimetic agents to maintain adequate renal perfusion is allowed. - Known or suspected hypersensitivity to, or inability to receive, tigecycline, tetracyclines, vancomycin, ceftazidime, imipenem/cilastatin, any aminoglycoside, and penicillin or other compounds related to these classes of antibacterial agents. - Concomitant treatment with ganciclovir. - Presence or history of brain lesions or presence of any uncontrolled central nervous system (CNS) disease, including epilepsy or unexplained seizures that, in the opinion of the investigator, would predispose subjects to imipenem-associated CNS adverse events, such as seizures or confusional states. - APACHE II score > 30. - Presence of any of the following laboratory findings: a. Neutropenia defined as an absolute neutrophil count < 1 X 109/L (< 1000/mm^3). b. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 10 times the upper limit of normal. c. Total bilirubin or alkaline phosphatase (AP) > 3 times the upper limit of normal, unless isolated hyperbilirubinemia was directly related to the acute process d. Calculated creatinine clearance (CLCR) < 41mL/min/1.73m^2 after adequate hydration. CLCR may be calculated from the serum creatinine concentration by the following equation, if serum creatinine is reported in mg/dL: Male: CLCR (mL/min) = (140 – age [years]) x weight [kg] 72 x serum Cr (mg/dL) Female: CLCR (mL/min) = 0.85 x CLCrmale (derived by above formula) If serum creatinine level is reported in µmol/L, the following formula will be used: Male: CLCR (mL/min) = (140 – age [years]) x weight [kg] 0.81 x serum Cr (µmol/L) Female: CLCR (mL/min) = 0.85 x CLCrmale (derived by above formula) BSA (m^2) = (weight [kg])0.425 x (height [cm])0.725 x 0.007184 (CLCR x1.73)/BSA= mL/min/1.73 m^2 - Anticipated discharge from the hospital in less than 7 days or the likelihood that the subject will not complete the course of treatment or follow-up. - Known or suspected concomitant bacterial infection requiring additional systemic antibacterial treatment. - Antibacterial drugs administered for > 24 hours to treat the current episode of suspected hospital-acquired pneumonia, UNLESS a repeat respiratory culture showed that a pathogen was resistant to that agent and/or the subject had worsening or no improvement in the clinical signs and symptoms of pneumonia. Note: Patient may not have failed one of the study medications or an agent of the same class. - Any investigational drugs taken or investigational devices used within 4 weeks before the first dose of test article. An investigational product is defined as lacking FDA or regional/local regulatory approved indications. - Known human immunodeficiency virus (HIV) infection - Immunosuppressive therapy that, in the opinion of the investigator, would decrease the subject’s ability to eradicate the infection (including chronic treatment with >10 mg/day of systemic prednisone or equivalent for greater than 3 weeks prior to randomization). - Life expectancy estimated at < 1 month - Pregnant women or nursing mothers - Female subjects of childbearing potential who do not agree to practice sexual abstinence or use a medically acceptable method of contraception throughout the duration of the study and for at least 1 month after the last dose of test article administration. - Any other major illness/condition that, in the investigator’s judgment, will substantially increase the risk associated with the subject’s participation in, and completion of, the study, or could preclude the evaluation of the subject’s response.
Total Enrollment:
Location and Contact Information:
Citrus Memorial Hospital *Recruiting*
Inverness, Florida, 34452
United States
Recruiting Vikram Shah 352-341-2100
Alachua General Hospital *Recruiting*
Gainesville, Florida, 32601
United States
Recruiting John Abernethy 352-331-8580
Baptist Hospital of East Tennessee *Recruiting*
Knoxville, Tennessee, 37920
United States
Recruiting D. Sellers 865-573-6443
St. Joseph's Hospital and Medical Center *Recruiting*
Phoenix, Arizona, 85013
United States
Recruiting John Siever 602-274-7195
Bay Pines VA Medical Center *Recruiting*
Bay Pines, Florida, 33744
United States
Recruiting C. Anderson 727-398-6661
Seven Rivers Community Hospital *Recruiting*
Crystal River, Florida, 34428
United States
Recruiting Vikram Shah 352-341-2100
North Fulton Regional Hospital *Recruiting*
Roswell, Georgia, 30076
United States
Recruiting Leena Dutta 770-751-2777
Greenville Hospital System *Recruiting*
Greenville, South Carolina, 29605
United States
Recruiting Lloyd Hayes 864-455-9831
Wellstar Kennestone Hospital *Recruiting*
Marietta, Georgia, 30060-1101
United States
Recruiting Stuart Simon 404-523-9031
Paradise Valley Hospital *Recruiting*
National City, California, 91950
United States
Recruiting William O'Riordan 619-422-1001
St. John's Hospital *Recruiting*
Springfield, Illinois, 62703
United States
Recruiting Donald Graham 217-527-4745
University of Nebraska Medical *Recruiting*
Omaha, Nebraska, 68918-5300
United States
Recruiting Austin Thompson 402-559-9101
Mercy Health Center *Recruiting*
Bentonville, Arkansas, 72712
United States
Recruiting Bruce Waldon 479-986-6094
eStudy Site *Recruiting*
Chula Vista, California, 91910
United States
Recruiting William O'Riordan 619-470-4236
University of Missouri Health Care *Recruiting*
Columbia, Missouri, 65212
United States
Recruiting Ravishanker Kamath 573-882-8157
Memorial Medical Center *Recruiting*
Springfield, Illinois, 62781
United States
Recruiting Donald Graham 506-855-1761
Odyssey Research Services *Recruiting*
Bismark, North Dakota, 58501
United States
Recruiting Anthony Tello 701-221-0900
Louisiana State University Health Sciences Center- Shreveport *Recruiting*
Shreveport, Louisiana, 71103
United States
Recruiting Robert Penn 318-675-5925
Doctor's Medical Center *Recruiting*
Modesto, California, 95350
United States
Recruiting Salah Bibi 209-527-4585
Joseph M. Still Burn Center at Doctors Hospital *Recruiting*
Augusta, Georgia, 30909
United States
Recruiting Bruce Friedman 706-651-6669
Jackson Park Hospital *Recruiting*
Chicago, Illinois, 60610
United States
Recruiting Bangalore Murthy 312-988-4500
Genesis Good Samaritan Hospital *Recruiting*
Zanesville, Ohio, 43071
United States
Recruiting Larry Cowan 740-246-4242
Additional Information:
Study ID Numbers: 3074A1-311-WW;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080496
Other Pneumonia Studies:
1. Ventilator-associated pneumonia / Hospital-acquired pneumonia requiring mechanical ventilatory support
2. Arginine Treatment of Acute Chest Syndrome (Pneumonia) in Sickle Cell Disease Patients
3. A Safety and Efficacy Study of Hospitalized Patients with Community-Acquired Pneumonia and Sepsis
4. Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia
5. Pediatric Community-Acquired Pneumonia
Related Studies:
Other Pneumonia Clinical Trials
Other Georgia Clinical Trials
Other Roswell Clinical Trials
Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia
|
|
|
|
|
|
|
|
